|
|
Blood, 1 March 2006, Vol. 107, No. 5, pp. 2079-2089.
Prepublished online as a Blood First Edition Paper on November 8, 2005; DOI 10.1182/blood-2004-11-4250.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups
Guido Bisping,
Martin Kropff,
Doris Wenning,
Britta Dreyer,
Sergey Bessonov,
Frank Hilberg,
Gerald J. Roth,
Gerd Munzert,
Martin Stefanic,
Matthias Stelljes,
Christian Scheffold,
Carsten Müller-Tidow,
Peter Liebisch,
Nicola Lang,
Jöelle Tchinda,
Hubert L. Serve,
Rolf M. Mesters,
Wolfgang E. Berdel, and
Joachim Kienast
From the Department of Medicine/Hematology and Oncology, University of Muenster, Muenster, Germany; the Boehringer Ingelheim Austria GmbH, Vienna, Austria; the Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; the Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; the University Hospital Großhadern, Department of Medicine III, Ludwig-Maximilians-University, Munich, Germany; and the Institute of Human Genetics, University of Muenster, Muenster, Germany.
In multiple myeloma (MM), both vascular endothelial (VEGF) and basic fibroblast growth factor (bFGF) promote tumor growth and survival. We have used the novel indolinone BIBF 1000 to study effects of simultaneous inhibition of VEGF, FGF and transforming growth factor- on MM cells and their interactions with bone marrow stroma cells (BMSCs). Both, in the absence and presence of myeloma-stroma cell contacts, BIBF 1000 abrogated BMSC-derived secretion of interleukin-6 (IL-6). In addition, BIBF 1000 directly induced apoptosis in t(4;14)–positive cell lines as well as in CD138+ marrow cells from patients with t(4;14) myeloma. To a similar extent, BIBF 1000 induced apoptosis in MM.1S and MM.1R cells carrying the translocation t(14;16). In case of MM.1S and other dexamethasone-sensitive t(14;16) cell lines, BIBF 1000 and dexamethasone had additive proapoptotic effects. Induction of apoptosis by BIBF 1000 was associated with inhibition of the mitogen-activated protein kinases (MAPK) pathway in t(4;14) and inhibition of the phosphatidyl-inositol-3 kinase/AKT pathway in t(14;16) cells. Apoptotic effects did not occur in t(4;14)–or t(14;16)–positive MM cells carrying n- or k-Ras mutations. The data provide the rationale for clinical evaluation of this class of targeted kinase inhibitors in MM with focus on defined cytogenetic subgroups.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Ikeda, T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al.
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Clin. Cancer Res.,
June 15, 2009;
15(12):
4028 - 4037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bisping, D. Wenning, M. Kropff, D. Gustavus, C. Muller-Tidow, M. Stelljes, G. Munzert, F. Hilberg, G. J. Roth, M. Stefanic, et al.
Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
Clin. Cancer Res.,
January 15, 2009;
15(2):
520 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Meads, L. A. Hazlehurst, and W. S. Dalton
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Clin. Cancer Res.,
May 1, 2008;
14(9):
2519 - 2526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Lapteva, M. R. Seethammagari, B. A. Hanks, J. Jiang, J. M. Levitt, K. M. Slawin, and D. M. Spencer
Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
Cancer Res.,
November 1, 2007;
67(21):
10528 - 10537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, M. Fulciniti, T. Hideshima, W. Song, M. Leiba, X.-F. Li, M. Rumizen, P. Burger, A. Morrison, K. Podar, et al.
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Blood,
September 1, 2007;
110(5):
1656 - 1663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar, G. Tonon, M. Sattler, Y.-T. Tai, S. LeGouill, H. Yasui, K. Ishitsuka, S. Kumar, R. Kumar, L. N. Pandite, et al.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
PNAS,
December 19, 2006;
103(51):
19478 - 19483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
